The increasing demand for biopharmaceuticals accelerates market growth.
The growing demand for biopharmaceuticals continues to be a major driving force behind the growth of the pharmaceutical market as of 2025. Biologics, which are derived from living organisms, are known for their high precision in targeting specific molecules or cells, leading to effective treatments with reduced side effects. This high level of precision is particularly useful in addressing complex conditions such as cancer, autoimmune diseases, and rare genetic disorders. Recent advancements are expanding the therapeutic applications of biopharmaceuticals. For example, in December 2024, the U.S. Food and Drug Administration approved the IL-31 inhibiting biologic Nemluvio (nemolizumab-ilto), developed by Galderma, for patients aged 12 and older with moderate to severe atopic dermatitis. This approval introduces a new option for managing this chronic skin condition. 【Contents】 ■ Market Overview ■ Market Analysis (Product Type, Application, Manufacturing Type, Source, End User) ■ Regional Market Analysis ■ Company Profiles
Inquire About This Product
basic information
Publisher: Visiongain Publication Month: March 2025 Report Language: English *For more details, please visit our website or refer to the sample materials.
Price range
P4
Delivery Time
P2
Applications/Examples of results
The research report provides data that serves as the basis for corporate strategies and decision-making. You can check the delivery image from the sample. We can also introduce reports from our offerings that are close to your preferences. Please feel free to contact us for any inquiries or consultations.
Company information
Data Resource Co., Ltd. provides valuable information and analytical data for business strategy planning, including the latest market information on telecommunications, computers, electronics, energy, and automotive-related sectors worldwide, as well as competitor strategies, the development of new technologies and services, regulations, and intellectual property.